Berlin Nov 9 (BUS) – German drugmaker BioNTech, which has partnered with Pfizer to develop the first widely used vaccine for COVID-19, announced that its profits grew again in the third quarter.
Mainz-based BioNTech reported a net profit of more than 3.2 billion euros ($3.7 billion) in the July-September period.
That compares to a loss of 210 million euros ($243 million) for the company in the same period a year ago and a second-quarter profit of about 2.8 billion euros ($3.2 billion). Immunizations with the Pfizer-BioNTech vaccine began in December.
BioNTech reported revenue of nearly €6.1 billion ($7.1 billion), up from €67.5 million ($78 million) in the third quarter of 2020.
It said more than two billion doses of the COVID-19 vaccine, marketed as Comirnaty, have been delivered this year as of November 2.
Based on a projected total of 2.5 billion doses, BioNTech said it expects full-year coronavirus vaccine revenue to reach 16 to 17 billion euros ($18.5 billion to $19.7 billion).
insult